🩹 EPO-Derived Anti-Inflammatory
ARA-290 (Cibinetide) Dosage Protocols: All Vial Sizes
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that retains tissue-protective and anti-inflammatory effects without erythropoietic activity.
Choose Your Vial Size
| Vial | Final volume | Concentration | One U-100 unit | |
|---|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg in 0.01 mL | Open protocol → |
| 16 mg | 2 mL | 8 mg/mL | 80 mcg in 0.01 mL | Open protocol → |
| 40 mg | 2 mL | 20 mg/mL | 200 mcg in 0.01 mL | Open protocol → |
Doses are the same research amounts across sizes; the vial size changes the concentration, so syringe units differ. Always use the table for your exact vial.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
⚠ Research Use Only.
How This Works
ARA-290 is derived from helix B of EPO and binds the innate repair receptor (IRR — a tissue-protective receptor distinct from EPO's erythropoietic receptor). It produces anti-inflammatory and tissue-protective effects without raising hematocrit.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects via IRR.
- Studied in diabetic neuropathy and sarcoidosis-related neuropathy.
- No erythropoietic effect — separate from EPO's blood effects.
Side Effect Profile
- Generally well-tolerated in trials.
- Mild injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet complements effects.
- Adequate B-vitamins support nerve health.
Injection Technique
- Subcutaneous, rotate sites.
References
1
Brines M et al. 'ARA 290, a non-erythropoietic peptide, attenuates pain in a rat model of diabetes' — Mol Med, 2014 View source ↗